Generics for Eliquis have Rx amount of ₩12.7 billion

Chong Kun Dang’s Liquisia ₩4.1 billion> Samjin’s Elxaban ₩2.4 billion> Yuhan’s Apixaban ₩1.7 billion

Generic companies decided to stop selling them all at once

It was found that Eliquis (Apixaban)'s cumulative prescription amount for generics, which faced a crisis of compensation for damages due to the Supreme Court decision made earlier this month, reached ₩12.7 billion.

 

With the sale of generics stopped at once after the Supreme Court ruling, generic companies have to pay a significant portion of ₩12.7 billion.

 

Eliquis' Rx performance is expected to rebound from next month.

 

However, the NOAC (new oral anticoagulant) market is stagnating, and it is unclear how long it will recover.

 

◆Eliquis' generics withdrew from the market after recording ₩12.7 billion Eliquis' generics withdrew from the market after recording ₩12.7 billion.

 

According to UBIST, a drug market research institute on the 26th, the cumulative prescription amount of Eliquis generics until the first quarter of this year is ₩12.7 billion.

 

By item, Chong Kun Dang’s Liquisia, ₩4.1 billion, Samjin's Elxaban ₩2.4 billion, Yuhan's Yuhan Apixaban, ₩1.7 billion, Hanmi’s Apixban, ₩1.1 billion, and Yooyoung's Yupix ,₩900 million.

 

Generics for Eliquis have rapidly increased their Rx performance since they were released through patent overcoming in the third quarter of 2019.

 

It surged to ₩400 million in the third quarter of 2019, ₩800 million in the fourth quarter, ₩1.4 billion in the first quarter of 2020, ₩1.8 billion in the second quarter, ₩2.4 billion in the third quarter, ₩2.7 billion in the fourth quarter, and ₩3.2 billionin the first quarter of this year.

 

However, the Supreme Court decision made earlier this month put the brakes on.

 

On the 9th, the Supreme Court overturned the first and second trial rulings in the dispute between BMS and generic companies over Eliquis' product patent on the 9th and sided with BMS.

 

BMS officially announced a claim for damages right after the ruling.

 

Generic companies stopped selling them.

 

It may be a turnaround in the revocation and reconciliation trial.

 

Quarterly Rx performance of Eliquis & Generics (unit: ₩100 million, data:UBIST)

The actual compensation amount is expected to be less than the cumulative prescription amount of each company.

 

This is because the amount of compensation for patent infringement is usually determined at the operating profit level, not sales.

 

Eliquis' generics, which were withdrawn from the market by a Supreme Court ruling, can reenter the market after September 2024, when their product patents expire.

 

Generic companies have finally overcome the formulation patent (2031) excluding the product patent in 2019.

 

◆Eliquis Rx cost reduced by 13%, Will earnings recover from the second quarter? Following the Supreme Court ruling and the subsequent suspension of generic sales, Eliquis is expected to be rebounded in prescriptions from next quarter.

 

Eliquis' Rx amount for the first quarter was ₩10.7 billion.

 

Compared to the same period last year (₩12.3 billion), it decreased by 13%.

 

Eliquis' Rx amount increased to ₩12.5 billion in the second quarter of 2019 just before the generic launch, but has declined since.

 

In the NOAC market, Daiichi Sankyo's Eliquis, Bayer's Xarelto and Boehringer Ingelheim's Pradaxa are competing.

 

It is the key to whether the existing prescription performance of generics will be entirely occupied by Eliquis or will be distributed to other items.

 

Another variable related to the recovery of Eliquis Rx results is the stagnation of the NOAC market.

 

The total NOAC market size increased to ₩46.9 billion until the third quarter of last year, but since then it has decreased for the second consecutive quarter.

 

The market size in the first quarter of this year was ₩44.8 billion.

 

Prescriptions for all three original items decreased excluding Lixiana.

 

Bayer's Xarelto decreased 3% from ₩12.3 billion in the first quarter of last year to ₩11.9 billion in the first quarter of this year.

 

Boehringer Ingelheim's Pradaxa decreased 16% from ₩3.8 billion to ₩3.2 billion.

 

Lixiana, which is the number one in the market, posted sales of ₩15.8 billion in the first quarter, the same as in the first quarter of last year.